Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments
Some, but not all, prior investigations suggest armodafinil may have utility as an adjunctive treatment in bipolar I depression.